Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study.
Yrsa Kolka JúlíusdóttirAndrim HaliliRuben CoronelFrederik FolkeChristian Torp-PedersenGunnar Hilmar GislasonTalip E ErogluPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
Use of SGLT-2i is associated with a reduced risk of OHCA compared with use of GLP-1a in type 2 diabetes.